Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and Thalidomide in Melanoma Brain Metastases
NCT00072163Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2003
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide and temozolomide in melanoma, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 5 years. Started Oct 2003; status: completed.
02
Drugs
thalidomidetemozolomide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00072163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072163.